Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2703-2026

Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536. Recall

Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536.

FDA recall Class II

Ongoing

FDA lists this Class II recall for Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2703-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Jun 8, 2026
FDA report date
Jul 15, 2026
Quantity in commerce
24,077 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536.

Affected model & UDI checker

Search the exact identifiers published for Z-2703-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
Not specifiedAtellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536.Check source notice00630414220505
FDA code information

Material Number: 11097536. UDI-DI: 00630414220505. All Lot Numbers.

View the original FDA recall notice

Why was this product recalled?

The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyzer which could cause falsely depressed or falsely elevated HbA1c patient results.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Siemens Healthcare Diagnostics, Inc. take?

Siemens Healthineers notified consignees on about 06/08/2026 via letter. Consignees were instructed to perform QC on each reagent well used for all A1c_E/A1c_H testing and enable "QC on Pack Change By Assay Type" to ensure QC is performed whenever testing transitions between wells. Enabling this setting will apply QC on Pack Change for all CH assays. If the lab uses Atellica CH to monitor QC, enable Patient QC Flagging to allow identification of potentially impacted patient results following a QC failure. Potentially impacted patient results will display a QC Fail flag and must be held from reporting and rerun after passing QC is obtained. If the lab uses Atellica Data Manager or other middleware to monitor QC, following a QC failure, hold all A1c_E/A1c_H samples processed after the failed QC event for review. Unload the reagent pack and load a new pack, repeat QC testing, and after acceptable QC results have been obtained, repeat any held A1c_E/A1c_H samples since the failed QC event. If repeated QC failures occur across consecutive wells, follow the lab s standard troubleshooting procedures to evaluate potential alternative causes for QC failure. Ensure to review the letter with the Medical Director to determine the appropriate course of action, including for any previously generated results, if applicable. Consignees were requested to complete and return the Field Correction Effectiveness Check Form, retain the letter with laboratory records and forward this letter to those who may have received this product, and as a result of these actions, track reagent inventory, associated with implementation of these actions, to report to Siemens Healthineers once a resolution is provided. A follow-up communication will be provided once the Customer Actions described above are no longer required. The follow-up communication will include an option for reporting A1c_E reagent inventory, including additional and/or discarded A1c_E/A1c_H tests or wells, to Sieme

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology